Medibank Private (MPV) Q2 2026 Earnings Report

The call conveyed positive operational momentum and strategic progress: group operating profit rose 6%, Medibank Health delivered strong double-digit revenue and profit growth, policyholder growth improved and the company completed a transformative primary care acquisition while maintaining a strong capital position and lifting the interim dividend. Headwinds exist—expense inflation, a revenue-mix shift toward lower-tier products, elevated claims dynamics in extras, negative hospital utilization (partly COVID-driven), lower investment income and competitive pressure from aggregators—but management presented mitigation plans, unchanged guidance ranges, and clear capacity to invest further in health businesses. Overall, the positives (earnings growth, Medibank Health acceleration, M&A scale, capital strength and customer engagement) outweigh the manageable near-term challenges.

Medibank kept FY‑26 guidance largely unchanged: resident claims per policy unit growth of 2.6–2.9% and an expectation that 1H revenue‑mix headwind (~150bps) will be better for the full year; group operating expenses of $690–695m for FY‑26 (including $10m of productivity savings) and non‑recurring cyber/IT security costs of ~ $35m; Medibank Health organic operating profit to grow in FY‑26 broadly in line with 1H26 plus ~A$6m from the Better Medical acquisition in 2H, with a FY‑30 Medibank Health earnings aspiration of at least A$200m and capacity to raise Tier‑2 debt; capital remains strong at 1.9x PCA and a 13.8% capital ratio (above the 10–12% target while holding capital against a A$250m APRA adjustment); interim dividend A$0.083 per share (up 6.4%, 76.8% payout of underlying NPAT); underlying EPS A$0.108 and underlying net investment return 2.74% (annualized spread to RBA cash rate 184bps).